Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy

Well, well, well…

Four in a row over the last month:

·         11/29/11: PTC-Roche licensing deal in Spinal Muscular Atrophy;

·         12/15/11: Shire-Atlas Venture alliance in rare diseases;

·         01/03/12: Enobia acquired by Alexion; and,

·         today:  Isis-Biogen Idec licensing deal in Spinal Muscular Atrophy 

Have orphan diseases ever attracted so much interest from Big Pharma and Venture Capital?